{
    "title": "Biogen bets on depression drug in $1.5 bln deal with Sage Therapeutics",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-8993469/Biogen-Sage-Therapeutics-enter-1-5-bln-deal-develop-sell-neurological-treatments.html",
    "date": "2020-11-27",
    "keywords": [
        "sage",
        "depression",
        "deal",
        "biogen",
        "roy",
        "postpartum",
        "agreement",
        "market",
        "zuranolone",
        "inc",
        "stake",
        "payment",
        "friday",
        "access",
        "therapy",
        "disorder",
        "mdd",
        "sage324",
        "tremor",
        "experience",
        "year",
        "center",
        "disease",
        "control",
        "prevention",
        "pipeline",
        "potential",
        "time",
        "uncertainty",
        "approval",
        "drug",
        "aducanumab",
        "premium",
        "closing",
        "price",
        "cash",
        "milestone",
        "country",
        "japan",
        "taiwan",
        "treatment",
        "zulresso",
        "afternoon",
        "trading",
        "analyst",
        "timing",
        "trial",
        "half",
        "reporting",
        "bengaluru",
        "editing",
        "arun",
        "koyyur"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}